TCM Biotech International Corp. (TPEX:4169)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
196.00
+5.00 (2.62%)
Feb 26, 2026, 2:53 PM CST
237.93%
Market Cap 11.57B
Revenue (ttm) 682.40M
Net Income (ttm) 21.08M
Shares Out 59.05M
EPS (ttm) 0.36
PE Ratio 549.08
Forward PE 90.32
Dividend 0.35 (0.18%)
Ex-Dividend Date n/a
Volume 437,670
Average Volume 136,731
Open 191.00
Previous Close 191.00
Day's Range 188.50 - 202.50
52-Week Range 43.65 - 202.50
Beta 0.01
RSI 70.25
Earnings Date Apr 17, 2026

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4169
Full Company Profile

Financial Performance

In 2024, TCM Biotech International's revenue was 666.53 million, a decrease of -31.26% compared to the previous year's 969.62 million. Earnings were 21.01 million, an increase of 13.12%.

Financial Statements

News

There is no news available yet.